KR890002067A - 질산 에스테르 유도체 - Google Patents

질산 에스테르 유도체

Info

Publication number
KR890002067A
KR890002067A KR1019880008995A KR880008995A KR890002067A KR 890002067 A KR890002067 A KR 890002067A KR 1019880008995 A KR1019880008995 A KR 1019880008995A KR 880008995 A KR880008995 A KR 880008995A KR 890002067 A KR890002067 A KR 890002067A
Authority
KR
South Korea
Prior art keywords
alkyl
compound
alkylene
hydrogen
amino
Prior art date
Application number
KR1019880008995A
Other languages
English (en)
Inventor
요이치 시오카와
고이치 다미모토
고헤이 다케나카
Original Assignee
후지사와 도모키치로
후지사와 야쿠힝 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 후지사와 도모키치로, 후지사와 야쿠힝 고교 가부시키가이샤 filed Critical 후지사와 도모키치로
Publication of KR890002067A publication Critical patent/KR890002067A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

내용없음.

Description

질산 아스테르 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 하기 일반식(Ⅰ)의 화합물 및 그 약학적 허용염.
    상기식에서, R1은 수소, 저급알킬, 할로(저급)알킬, 할로겐, 적당한 치환기를 가지는 아릴, 헤테로사이클기, 적당한 치환기로 치환될 수 있는 아미노, 또는 N,N-디(저급)알킬아미노(저급)알킬이며, R2는 수소, 저급알킬 또는 N-[니트로옥시(저급)알킬]카르바모일이며, X는 -O- 또는 -S-이며, Y는 단일결합, 저급알킬렌 또는 저급 알케닐렌이며, 및 Z는 적당한 치환기로 치환될 수 있는 저급알킬렌 또는 저급알킬렌옥시(저급)알킬렌이다.
  2. 제1항에 있어서, 상기식중 R1은 수소, 저급알킬, 할로(저급)알킬, 할로겐, 니트로를 가질 수 있는 아릴, 1 내지 4개의 질소원자를 가지는 5-또는 6-원자 방향족 헤테로사이클기, 질소원자 및 산소원자를 가지는 5-또는 6-원자 지방족 헤테로모노사이클기, 1 또는 2개의 질소원자를 가지는 5-또는 6-원자 지방족 헤테로모노사이클기, 아실을 가질 수 있는 아미노, N-저급알킬 아미노, N,N-디(저급)알킬아미노, N-저급알킬-N-아실아미노 또는 N,N-디(저급)-알킬아미노(저급)알킬이며, 및 Z는 1 또는 24ㅐ의 니트로옥시로 치환될 수 있는 저급알킬렌인 것을 특징으로하는 화합물.
  3. 제2항에 있어서, 상기식중 R1은 수소, 저급알킬, 할로(저급)알킬, C6-C12아릴, 니트로를 가지는 C6-C12아릴, 피리딜, 모풀니노, 피레피디노, 아미노, 저급알카노일아미노, 고급알카노일아미노, C6-C12아로일ㅇ아미노, 저급알콕시카르보닐아미노, N-저급알킬아미노, N,N-디(저급)알킬아미노, N-저급알킬-N-저급알카노일아미노, 3-저급알킬우레이도 또는 N,N-디(저급)알킬아미노(저급)알킬이며, 및 Z는 저급알킬렌, 1 또는 2개의 니트로옥시를 가지는 저급알킬렌 또는 저급알킬렌옥시(옥시)알킬렌 인것을 특징으로하는 화합물.
  4. 제3항에 있어서, 상기식중 R1은 수소, 메틸, 부릴, 트리플루오로메틸, 클로로, 페닐, 니트로페닐, 피리딜, 모풀리노, 피페리디노, 아미노, 아세트아미도, 부티르아미도, 라ㅜ로일아미노, 벤즈아미도, 메톡시카프보닐아미노, N-메틸아미노, N,N-디메틸아미노, N-메틸-N-아세틸아미노, 3-메탈우레이도 또는 N,N-디메틸- 아미노메틸이며, R2는 수소, 메틸 또는 N-(니트로옥시에틸)카르바모일이며, Y는 단일결합, 메틸렌 또는 비닐렌이며, 및 Z는 에틸렌, 트리메틸렌, 테트라메틸렌, 1-메틸-1-니트로옥시메틸에틸렌, 1,1-비스(니트로옥시메틸)에틸렌, 2-니트로옥시트리메틸렌 또는 에틸렌옥시에틸렌인 것을 특징으로하는 화합물.
  5. 제4항에 있어서, 상기식중 X는 -S-이고, Y는 단일결합이며, 및 Z는 에틸렌인 것을 특징으로하는 화합물.
  6. 제5항에 있어서, N-(2-니트로옥시에틸)-2-메틸-4-티아졸카르복스아미드 또는 그 히드로클로라이드인 것을 특징으로하는 화합물.
  7. 제5항에 있어서, N-(2-니트로옥시에틸)-4-티아졸 카르복스아미드인 것을 특징으로하는 화합물.
  8. 제1항에 있어서, N-(2-니트로옥시에틸)-4-티아졸 카르복스아미드인 것을 특징으로하는 화합물.
    상기식에서, R1은 수소 또는 저급알킬이며, R2는 수소이며, X는 -S-이며, Y는 단일결합이며, 및 Z는 저급알킬렌이다.
  9. 다음 반응 단계를 포함하는 것을 특징으로 하는 하기식(Ⅰ)의 화합물 또는 그 염의 제조방법.
    (1) 하기식(Ⅱ)의 화합물 또는 카르복시기에서의 반응성 유도체 또는 그 염을 하기식(Ⅲ)의 화합물 또는 아미노기에서의 반응성 유도체 또는 그 염과 반응시켜 하기식(Ⅰ)의 화합물 또는 그 염을 제조하는 단계, 및 (2) 하기식(Ⅳ)의 화합물 또는 그 염을 질산화제와 반응시켜 하기식(Ⅰ)의 화합물 또는 그 염을 제조하는 단계.
    상기식에서, R1은 수소, 저급알킬, 할로(저급)알킬, 할로겐, 적당한 치환기를 가질수 있는 아릴, 헤테로사이클기, 적당한 치환기로 치환될 수 있는 아미노, 또는 N,N-디(저급)알킬아미노(저급)알킬이며, R2는 수소, 저급알킬 또는 N-[니트로옥시(저급)알킬]카르바모일이며, X는 -O- 또는 -S-이며, Y는 단일결합, 저급알킬렌 또는 저급 알케닐렌이며, 및 Z는 적당한 치환기로 치환될 수 있는 저급알킬렌 또는 저급알킬렌옥시(저급)알킬렌이다.
    상기식에서, Rq,R2,X 및 Y는 상기에서 정의한 바와 같다.
    상기식에서, Z는 상기에서 정의한 바와 같다.
    상기식에서, R1,R2,X,Y 및 Z는 상기에서 정의한 바와같다.
  10. 약학적으로 허용될 수 있는 비독성 담체 또는 부형제와 조합된 제1항의 화합물을 포함하는 것을 특징으로하는 약학적 조성물 또는 그 약학적 허용염.
  11. 활성제로서 제1항의 화합물 또는 그 약학적 허용염을 불활성 담체와 혼합하는 것을 포함하는 약학적 조성물의 제조방법.
  12. 혈관질병의 치료에 제1항의 화합물 또는 그 약학적 허용염을 사용하는 방법.
  13. 제1항의 화합물 또는 그 약학적 허용염을 투여하는 것을 포함하는 혈관질병의 치료방법.
  14. 하기식(Ⅳ)의 화합물 및 그 염.
    상기식중에서, R1은 수소, 저급알킬, 할로(저급)알킬, 할로겐, 적당한 치환기를 가질 수 있는 아릴, 헤테로사이클기, 적당한 치환기로 치환될 수 있는 아미노 또는 N,N-디(저급)알킬아미노(저급)알킬이며, Ra 2는 수소, 저급알킬 또는 N-[히드록시(저급)알킬]카르바모일이며, X는 -O- 또는 -S-이며, Y는 단일 결합, 저급알킬렌 또는 저급알케닐렌이며, 및 Z은 적당한 치환기로 치환될 수 있는 저급알킬렌 또는 저급알킬렌옥시(저급)알킬렌이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880008995A 1987-07-20 1988-07-19 질산 에스테르 유도체 KR890002067A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8717068 1987-07-20
GB878717068A GB8717068D0 (en) 1987-07-20 1987-07-20 Nitric ester derivative

Publications (1)

Publication Number Publication Date
KR890002067A true KR890002067A (ko) 1989-04-07

Family

ID=10620954

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880008995A KR890002067A (ko) 1987-07-20 1988-07-19 질산 에스테르 유도체

Country Status (19)

Country Link
US (2) US4923886A (ko)
EP (1) EP0300400B1 (ko)
JP (1) JPH0228167A (ko)
KR (1) KR890002067A (ko)
CN (1) CN1021046C (ko)
AT (1) ATE102928T1 (ko)
AU (1) AU623858B2 (ko)
DE (1) DE3888415T2 (ko)
DK (1) DK375988A (ko)
FI (1) FI883402A (ko)
GB (1) GB8717068D0 (ko)
HU (1) HU203227B (ko)
IL (1) IL86959A (ko)
MX (1) MX12317A (ko)
NO (1) NO172049C (ko)
PH (1) PH24481A (ko)
PT (1) PT88019B (ko)
SU (2) SU1706388A3 (ko)
ZA (1) ZA884987B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101045041B1 (ko) * 2009-10-27 2011-06-28 (주)에스엠이엔지 봉합침 제조방법

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3941438A1 (de) * 1989-12-15 1991-06-20 Hoechst Ag Neue 2-substituierte 4-(3-alkyl-5-tert.-butyl-4-hydroxy-phenyl)-thiazole, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
IT1243367B (it) * 1990-07-26 1994-06-10 Italfarmaco Spa Derivati acidi benzoici sostituiti ad attivita' cardiovascolare
US5298516A (en) * 1991-03-27 1994-03-29 Sankyo Company, Limited Thiazolidone compounds and method of using the same as a vasodilator
JP3454531B2 (ja) * 1991-11-07 2003-10-06 三共株式会社 ニトロキシアルキルアミド誘導体
IT1256450B (it) * 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
CN1092649C (zh) * 1994-12-15 2002-10-16 三共株式会社 噻唑烷酮化合物或以其作为有效成分的心绞痛治疗剂或预防剂
CA2214386C (en) * 1995-03-02 2001-12-04 Sadao Ishihara Optically active thiazolidinone derivatives
US5925658A (en) * 1995-03-02 1999-07-20 Sankyo Company, Limited Optically active thiazolidinone derivative
IL120531A (en) * 1997-03-26 2006-12-31 Yissum Res Dev Co Nitric oxide donors and pharmaceutical compositions containing them
WO2000062778A1 (en) 1999-04-15 2000-10-26 Bristol-Myers Squibb Co. Cyclic protein tyrosine kinase inhibitors
US6933308B2 (en) * 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
US7273866B2 (en) * 2002-12-20 2007-09-25 Bristol-Myers Squibb Company 2-aryl thiazole derivatives as KCNQ modulators
US8134010B2 (en) * 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
US7968575B2 (en) * 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
WO2005105765A1 (en) * 2004-05-05 2005-11-10 Renopharm Ltd. Nitric oxide donors and uses thereof
DE102009037555A1 (de) * 2009-08-13 2011-03-03 Synovo Gmbh Ein neuartiges, schonendes Verfahren zur direkten Nitrierung von Hydroxyl-, Thiol- und Aminogruppen in organischen Molekülen mittels in situ generiertem Kohlensäuredinitrat
WO2013060673A1 (en) * 2011-10-24 2013-05-02 Nicox S.A. Quinone based nitric oxide donating compounds
RU2015105097A (ru) * 2012-08-23 2016-10-10 Кардиолинкс Аг Композиции аминоалкилнитрата с пролонгированным высвобождением

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200640A (en) * 1976-04-02 1980-04-29 Chugai Seiyaku Kabushiki Kaisha Nitric ester of N-(2-hydroxyethyl)nicotinamide and pharmaceutical use
DE3244178A1 (de) * 1982-11-30 1984-05-30 Bayer Ag, 5090 Leverkusen 1,4-dihydropyridinderivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE3433383A1 (de) * 1984-09-12 1986-03-20 Boehringer Mannheim Gmbh, 6800 Mannheim Neue phenyl-acetonitril-derivate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101045041B1 (ko) * 2009-10-27 2011-06-28 (주)에스엠이엔지 봉합침 제조방법

Also Published As

Publication number Publication date
JPH0228167A (ja) 1990-01-30
FI883402A0 (fi) 1988-07-18
CN1021046C (zh) 1993-06-02
HUT47551A (en) 1989-03-28
GB8717068D0 (en) 1987-08-26
PT88019A (pt) 1989-06-30
DE3888415D1 (de) 1994-04-21
AU1919988A (en) 1989-01-27
EP0300400A1 (en) 1989-01-25
MX12317A (es) 1993-09-01
NO172049B (no) 1993-02-22
PT88019B (pt) 1995-03-01
HU203227B (en) 1991-06-28
US4923886A (en) 1990-05-08
IL86959A0 (en) 1988-12-30
DK375988D0 (da) 1988-07-06
DE3888415T2 (de) 1994-07-14
JPH0331709B2 (ko) 1991-05-08
US5010093A (en) 1991-04-23
CN1031226A (zh) 1989-02-22
EP0300400B1 (en) 1994-03-16
PH24481A (en) 1990-07-18
ATE102928T1 (de) 1994-04-15
ZA884987B (en) 1989-05-30
DK375988A (da) 1989-01-21
AU623858B2 (en) 1992-05-28
NO883208L (no) 1989-01-23
FI883402A (fi) 1989-01-21
SU1760984A3 (ru) 1992-09-07
IL86959A (en) 1992-12-01
SU1706388A3 (ru) 1992-01-15
NO883208D0 (no) 1988-07-19
NO172049C (no) 1993-06-02

Similar Documents

Publication Publication Date Title
KR890002067A (ko) 질산 에스테르 유도체
HUT68856A (en) Acridine derivatives, pharmaceutical compositions comprising the same compouds as effective substances and a process for producing the compounds and the pharmaceutical compositions
CA2113726A1 (en) Use of tetrahydrocarbazone derivatives as 5ht1 receptor agonists
HUT70502A (en) Amidino derivatives, pharmaceutical compns. contg. them and process to prepare them
NO179638C (no) Analogifremgangsmåte for fremstilling av tiazolderivater
DE69110828D1 (de) Heterozyklische Aminderivate, deren Herstellung und deren Verwendung.
GB1212460A (en) Naphthacene derivatives
HUT70052A (en) Process for producing pharmaceutical compositions containing pirimidone derivatives in the treatment of certain airway or skin diseases
OA09349A (fr) "Nouveaux dérivés du 3-aminochromane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent".
KR870003098A (ko) 치환된 3-(4-페닐-1-피페라지닐)알킬퀴나졸린-2,4-(1h,3h)디온의 제조방법
KR920006346A (ko) 3-(1h-인다졸-3-일)-4-피리딘아민, 이의 제조방법, 이의 제조를 위한 중간체 및 약제로서의 이의 용도
KR870008862A (ko) 1-2-4-트리지아논 유도체의 제조방법
HU896174D0 (en) Process for the preparation of heterocyclic derivatives fusionated 1,2,3,4-tetrahydro-acridine and pharmaceutical compositions thereof
KR910000744A (ko) 4,5,5a,6-테트라하이드로-3H-이속사졸로[5,4,3-kl]아크리딘 유도체, 이의 제조 방법 및 약제로서의 이의 용도
KR100215609B1 (ko) 퀴노질린 유도체를 포함하는 식욕증진제로서 유용한 약제학적 조성물
KR940003920A (ko) 테트라히드로나프탈렌 유도체, 이것의 제법 및 이것의 치료에의 이용
KR970703327A (ko) 산 아미드 유도체 및 이들의 제조 방법(acid amide derivatives and process for the preparation thereof)
KR890006239A (ko) N-함유 헤테로 사이클릭 화합물을 함유하는 심장 보호제 및 허혈성 질환 치료제 및 n-함유 헤테로 사이클릭 화합물의 제조 방법
ATE165829T1 (de) Nootrope wirkstoffe
FR2633292B1 (fr) Nouveaux derives de la 20,21-dinoreburnamenine substitues en 15 par un groupement amine, leur procede de preparation et les intermediaires ainsi obtenus, leur application comme medicaments et les compositions pharmaceutiques les reenfermant
ES8603180A1 (es) Procedimiento de obtencion de la n-(2-tenoil)-n-(2-ceto-2, 3, 4, 5-tetrahidro-tiofen-3-il)-amina

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid